271 related articles for article (PubMed ID: 33919156)
1. Store-Operated Calcium Entry: Shaping the Transcriptional and Epigenetic Landscape in Pancreatic Cancer.
Kutschat AP; Johnsen SA; Hamdan FH
Cells; 2021 Apr; 10(5):. PubMed ID: 33919156
[TBL] [Abstract][Full Text] [Related]
2. Aberrant NFATc1 signaling counteracts TGFβ-mediated growth arrest and apoptosis induction in pancreatic cancer progression.
Hasselluhn MC; Schmidt GE; Ellenrieder V; Johnsen SA; Hessmann E
Cell Death Dis; 2019 Jun; 10(6):446. PubMed ID: 31171768
[TBL] [Abstract][Full Text] [Related]
3. ORAI3 silencing alters cell proliferation and promotes mitotic catastrophe and apoptosis in pancreatic adenocarcinoma.
Dubois C; Kondratska K; Kondratskyi A; Morabito A; Mesilmany L; Farfariello V; Toillon RA; Ziental Gelus N; Laurenge E; Vanden Abeele F; Lemonnier L; Prevarskaya N
Biochim Biophys Acta Mol Cell Res; 2021 Jun; 1868(7):119023. PubMed ID: 33798603
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
[TBL] [Abstract][Full Text] [Related]
6. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma.
Huang S; Li Y; Hu J; Li L; Liu Z; Guo H; Jiang B; Chen J; Li J; Xiang X; Deng J; Xiong J
J Cell Mol Med; 2021 May; 25(9):4275-4286. PubMed ID: 33834618
[TBL] [Abstract][Full Text] [Related]
7. The promise of epigenomic therapeutics in pancreatic cancer.
Lomberk GA; Iovanna J; Urrutia R
Epigenomics; 2016 Jun; 8(6):831-42. PubMed ID: 27337224
[TBL] [Abstract][Full Text] [Related]
8. Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma.
Bauden M; Kristl T; Sasor A; Andersson B; Marko-Varga G; Andersson R; Ansari D
BMC Cancer; 2017 Dec; 17(1):810. PubMed ID: 29197353
[TBL] [Abstract][Full Text] [Related]
9. Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux.
Carozzo A; Yaneff A; Gómez N; Di Siervi N; Sahores A; Diez F; Attorresi AI; Rodríguez-González Á; Monczor F; Fernández N; Abba M; Shayo C; Davio C
Mol Pharmacol; 2019 Jul; 96(1):13-25. PubMed ID: 31043460
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells.
Gailhouste L; Liew LC; Hatada I; Nakagama H; Ochiya T
Cell Death Dis; 2018 May; 9(5):468. PubMed ID: 29700299
[TBL] [Abstract][Full Text] [Related]
11. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.
McCleary-Wheeler AL; Lomberk GA; Weiss FU; Schneider G; Fabbri M; Poshusta TL; Dusetti NJ; Baumgart S; Iovanna JL; Ellenrieder V; Urrutia R; Fernandez-Zapico ME
Cancer Lett; 2013 Jan; 328(2):212-21. PubMed ID: 23073473
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution.
Hernández-Muñoz I; Skoudy A; Real FX; Navarro P
Pancreatology; 2008; 8(4-5):462-9. PubMed ID: 18724072
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
[TBL] [Abstract][Full Text] [Related]
14. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
15. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer.
Funel N; Giovannetti E; Pollina LE; del Chiaro M; Mosca F; Boggi U; Campani D
Expert Rev Mol Diagn; 2011 Sep; 11(7):695-701. PubMed ID: 21902531
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
17. An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma.
Aier I; Semwal R; Dhara A; Sen N; Varadwaj PK
PLoS One; 2019; 14(10):e0223554. PubMed ID: 31622355
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
19. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells.
Ma Z; Vocadlo DJ; Vosseller K
J Biol Chem; 2013 May; 288(21):15121-30. PubMed ID: 23592772
[TBL] [Abstract][Full Text] [Related]
20. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
